期刊文献+

阿立哌唑与利培酮治疗精神分裂症的对照研究 被引量:2

下载PDF
导出
摘要 目的比较阿立哌唑与利培酮治疗精神分裂症的疗效与安全性。方法将60例精神分裂症患者随机分为阿立哌唑组(n=30)和利培酮组(n=30)进行治疗,疗程8周。采用阳性和阴性症状表(PANSS)临床总体印象量表(CGI)评定临床疗效,用副反应量表(TESS)、锥体外系副反应量表(RSE-SE)评定不良反应。结果两组从治疗第1周末起PANSS总分及阳性症状量表得分均明显下降,差异无显著性。阿立哌唑组从治疗第1周末起阴性症状量表得分明显下降,而利培酮组从治疗第2周末起阴性症状量表得分才有明显下降,差异有显著性。8周后阿立哌唑的治疗有效率为90%,利培酮有效率为86.7%,差异无显著性。阿立哌唑组的不良反应主要为头痛、恶心呕吐、失眠、利培酮组的不良反应以锥体外系反应(EPS)为主。其次为血浆催乳素(PRL)浓度增高,而阿立哌唑组的EPS发生少且轻,对内分泌系统几乎无影响,差异有统计学意义(P<0.01)。结论阿立哌唑与利培酮治疗精神分裂症均疗效肯定,而前者更安全,依从性更好。
作者 李晓华
出处 《中国实用医药》 2009年第18期166-167,共2页 China Practical Medicine
  • 相关文献

参考文献6

  • 1吴仁容,李乐华.新型抗精神病药:阿立哌唑[J].国外医学(精神病学分册),2004,31(3):177-179. 被引量:380
  • 2Bowles TM, Levin GM. Aripiprszole: a new atypicat antipsychotic drug. Ann pharmacohter ,2003,37 (5) :687.
  • 3Different effects on D dopamine recept and prolactin gene e-xxpress, by haloperidoe and airpiprazole in the rat pituitarr. Mo-lecular Brain Research, 1998,55:285 -292.
  • 4Shapine DA, Renock S, Arrington E, et al. Arip: prazote, a new novetatypicaf ant ipsychotic drug with a unique and robust pharmacology. Neuropsy chopharmacology, 2003,16:221-225.
  • 5Shha AR,carson WH,AH MV,et al. Efficacy and safety of aripiprrazote and risperidone VS placebo in patients with soh izophrenia and schizoaffective disorder. WJ Biot psyehiat, 2001,2 ( sup ) : 305 -308.
  • 6Potkin SG, Shah AR, Kujawa, et al. Apripiprazofe, an antipsychotic with a novaf mechanism of action, and risper done VS placebo in pat-ients with schizophrenia and schizaoaffecive dosorder. Arch Gen p -sychiatry, 2003,60 ( 7 ) : 681-690.

二级参考文献13

  • 1Kilkuchiet T,et al:J Pharmacol Exp Ther.1995;274(1):329—336.
  • 2Semba J,et al:Neuropharmacology,1995;34(7):785—791.
  • 3Fujikawa M,et al:Pharmacol Biochem Behav.1996;53(4):903—909.
  • 4Alison P,et al:Molecular Brain Research,1998;55:285—292.
  • 5Inoue A。et al:Brain Res Mol Brain Res.1998;55:285—292.
  • 6Shapine DA,et al:Neuropsychopharmacology,2003:1 46(5):214—216.
  • 7Bruce S:Drugs Research and Development,1999;2(1):47—48.
  • 8Stephen M,et al:Drugs oI the Future,2000;25(9):961—963.
  • 9Susman ED:Drugs oI the Future,1997;22(9):1029—1030.
  • 10McGavin JK,et al:CNS Drugs,2002;16(11):779—788.

共引文献379

同被引文献18

  • 1王刚平,颉瑞,裴根祥,张永录.阿立哌唑的临床应用(一)——阿立哌唑与氯氮平治疗精神分裂症对照研究[J].临床精神医学杂志,2006,16(1):44-45. 被引量:43
  • 2Teori Y,Miwa T,Tottori K,et al.Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic[J].European J Pharmacology,2005,515(16):10-19.
  • 3Aihara K,Shimada J,Miwa T,et al.The novel antipsychotic aripiprazole is a partial agonist at short and long isoforms of D2 receptors linked to the regulation of adenylyl cyclase activity and prolactin release[J].Brain Research,2004,1(1003):9-17.
  • 4Burris KD,Molski TF,Xu C,et al.Aripiprazole,a novel antipsychotic,is a high-affinity partial agonist at human dopamine D2 receptors[J].J Pharmacol Exp Ther,2002,302(3):381-389.
  • 5Jordan S,Koprivica V,Chen R,et al.The antipsychotic aripiprazole is a potent,partial agonist at the human 5-HT(1A) receptor[J].Eur J Pharmacol,2002,441(3):137-140.
  • 6McQuade RD,Burris KD,Jordan S,et al.Arpiprazole:a dopamine-serotonin system atabilizer[J].Int J Neuropsychopharmacol,2002,11(5):S176.
  • 7Marder SR,McQuade RD,Stock E,et al.Aripiprazole in the treatment of schizophrenia:safety and tolerability in short-term,placebo-controlled trials[J].Schizophrenia Research,2003,61 (2):123-136.
  • 8McQuade RD,Stock E,Marcus R,et al.A comparison of weight change during treatment with olanzapine or aripiprazole:results from a randomized,double-blind study[J].J Clin Psychiatry,2004,65(suppl 18):47-56.
  • 9张明圆.精神科评定量表手册.2版.长沙:湖南科技技术出版社,1993:198-203.
  • 10黄雄,杜文佳,薛仕健,童梓顺,蒋泽宇.阿立哌唑与利培酮治疗精神分裂症的临床疗效及对血清催乳素的影响[J].药物不良反应杂志,2008,10(2):77-80. 被引量:18

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部